Brittany Dustman

Q: What is Brittany Dustman email address?

Email Brittany Dustman at brittany.dustman@bms.com. This email is the most updated Brittany Dustman's email found in 2026.

Q: How to contact Brittany Dustman?

To contact Brittany Dustman send an email to brittany.dustman@bms.com.

Director, Global Regulatory Affairs - Cell Therapy at Bristol Myers Squibb | Greater Philadelphia

About Brittany Dustman

Brittany Dustman serves as the Director of Global Regulatory Affairs for Cell Therapy at Bristol Myers Squibb, where she leverages her extensive expertise in regulatory affairs to drive the development and commercialization of innovative therapies. With a robust background in oncology, immunology, and respiratory therapeutic areas, Brittany is adept at navigating the complexities of regulatory landscapes for small molecules, biologics, and advanced therapies like cell and gene therapies.

In her current role, Brittany is pivotal in shaping the U.S. regulatory strategy for a marketed cell therapy, focusing on expanding its indications through a supplemental Biologics License Application (sBLA). She is responsible for coordinating the preparations for this major application, which includes strategizing for a pre-sBLA meeting with the FDA. Brittany collaborates closely with cross-functional teams, ensuring that the objectives, content, and overall strategy align with regulatory requirements and market needs. Her ability to integrate insights from clinical trials and pharmacoeconomics into regulatory submissions enhances the likelihood of successful outcomes, ultimately benefiting patients in need of cutting-edge therapies.

Brittany’s skills in medication therapy management, clinical pharmacy, and pharmacology further enrich her contributions, allowing her to effectively communicate complex scientific data to regulatory authorities while advocating for patient access to life-changing treatments. Her commitment to excellence in regulatory affairs not only supports Bristol Myers Squibb’s mission to deliver transformative therapies but also positions her as a thought leader in the evolving landscape of cell therapy regulation.

Brittany Dustman Work